SEC Form 4 · accession 0001628280-26-042042
Arcutis Biotherapeutics, Inc. · ARQT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Terrie Curran
Director
Period of report
Jun 5, 2026
Accepted (ET)
Jun 9, 2026 · 9:21 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001787306
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 5, 2026 | A | 5,778 | $0.00 | A | 23,526 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F2 | $21.23 | Jun 5, 2026 | A | 16,667 | A | — | Jun 5, 2036 | Common Stock | 16,667 | 16,667 | D |
Explanation of responses
- F1Represents Restricted Stock Units ("RSUs") granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof, which shall occur on the earlier of the first anniversary of the grant date, June 5, 2026, or immediately before the next annual meeting of stockholders, subject to the continued service through the vesting date. Upon vesting of the RSUs, the settlement has been deferred by the Reporting Person, pursuant to the terms of the RSU Deferral Election Form adopted on December 22, 2025, maintained by the Company.
- F2The underlying shares subject to the option vest and become exercisable as to 100% on the earlier of the first anniversary of the grant date, June 5, 2026, or immediately before the next annual meeting of stockholders, subject to the continued service through the vesting date.